A novel HPLC-DAD method for simultaneous determination of febuxostat and diclofenac in biological samples: Pharmacokinetic outcomes

Simple item page
dc.contributor.authorEl-Yazbi, Fawzy A.
dc.contributor.authorAmin, Omayma Abdel Razak
dc.contributor.authorEl-Kimary, Eman I.
dc.contributor.authorKhamis, Essam F.
dc.contributor.authorYounis, Sameh E.
dc.contributor.authorElKhatib, Mohammed A.W.
dc.contributor.authorEl-Yazbi, Ahmed F.
dc.contributor.departmentPharmacology and Toxicology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:39:37Z
dc.date.available2025-01-24T11:39:37Z
dc.date.issued2019
dc.description.abstractAim: To develop a simple HPLC-DAD method for simultaneous determination of febuxostat (FEB) and diclofenac (DIC) in biological samples to assess pharmacokinetic outcomes of their coadministration. Methodology & results: Sample preparation was performed by liquid-liquid extraction. Drugs analysis was done on C18 column using methanol-formic acid pH 2.1 (76:24, v/v) as mobile phase and time-programmed UV detection. Lower limits of quantitation for FEB and DIC were 10 and 20 ng/ml, respectively. Baseline pharmacokinetics were similar to published data on either drug alone. Coadministration led to more than twofold increase in FEB C max and AUC together with a reduced hepatic uptake in rats. Conclusion: DIC interfered with initial distribution and terminal clearance of FEB potentially due to reduced FEB hepatic uptake. © 2018 Newlands Press.
dc.identifier.doihttps://doi.org/10.4155/bio-2018-0219
dc.identifier.eid2-s2.0-85058491865
dc.identifier.pmid30475064
dc.identifier.urihttp://hdl.handle.net/10938/29299
dc.language.isoen
dc.publisherFuture Medicine Ltd.
dc.relation.ispartofBioanalysis
dc.sourceScopus
dc.subjectDiclofenac
dc.subjectFebuxostat
dc.subjectHplc-dad
dc.subjectHuman plasma
dc.subjectLiver uptake
dc.subjectPharmacokinetics
dc.subjectAdult
dc.subjectAnimals
dc.subjectArea under curve
dc.subjectCalibration
dc.subjectChromatography, high pressure liquid
dc.subjectCross-over studies
dc.subjectHealthy volunteers
dc.subjectHumans
dc.subjectLiquid-liquid extraction
dc.subjectLiver
dc.subjectMale
dc.subjectRats
dc.subjectRats, sprague-dawley
dc.subjectReproducibility of results
dc.subjectSensitivity and specificity
dc.subjectTissue distribution
dc.subjectArea under the curve
dc.subjectArticle
dc.subjectDiode array detector
dc.subjectDrug clearance
dc.subjectDrug determination
dc.subjectDrug distribution
dc.subjectDrug uptake
dc.subjectHigh performance liquid chromatography
dc.subjectHuman
dc.subjectHuman experiment
dc.subjectLimit of detection
dc.subjectLimit of quantitation
dc.subjectLiquid liquid extraction
dc.subjectMaximum concentration
dc.subjectNonhuman
dc.subjectNormal human
dc.subjectRat
dc.subjectAnimal
dc.subjectBlood
dc.subjectCrossover procedure
dc.subjectMetabolism
dc.subjectReproducibility
dc.subjectSprague dawley rat
dc.titleA novel HPLC-DAD method for simultaneous determination of febuxostat and diclofenac in biological samples: Pharmacokinetic outcomes
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2019-7861.pdf
Size:
589.94 KB
Format:
Adobe Portable Document Format
Download

Collections

Pharmacology and Toxicology